Challenges in the histopathologic diagnosis of histiocytic neoplasms

16Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

Abstract

Histiocytic neoplasms, including Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD), and Rosai-Dorfman disease (RDD), present a diagnostic challenge due to nonspecific fibroinflammatory infiltrates and a diverse clinical presentation. The pathologist can play a key role in classification of these disorders through multidisciplinary collaboration and correlation of pathologic features with clinical and radiologic findings. The histopathologic differential diagnosis is broad, requiring knowledge of the possible diagnoses at each specific anatomic site, and a careful assessment to exclude other inflammatory and neoplastic disorders. An immunohistochemistry panel including CD163, CD1a, langerin, S100, Factor XIIIa, OCT2, and BRAF V600E can provide definitive diagnosis in LCH and RDD, whereas ECD requires classic clinical features as well as confirmation of an activating MAPK pathway mutation by genetic studies.

Cite

CITATION STYLE

APA

Rech, K. L., & He, R. (2021, November 1). Challenges in the histopathologic diagnosis of histiocytic neoplasms. JNCCN Journal of the National Comprehensive Cancer Network. Harborside Press. https://doi.org/10.6004/jnccn.2021.7098

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free